{"gene":"ARAF","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1995,"finding":"A-Raf kinase domain (deltaA-Raf:ER) activates MEK and ERK upon estradiol-induced activation in mammalian cells, but phosphorylates MEK1 in vitro at least 500-fold less efficiently than deltaB-Raf:ER and ~10-fold less efficiently than deltaRaf-1:ER, demonstrating A-Raf has intrinsically lower MEK kinase activity than the other Raf isoforms.","method":"Inducible Raf:ER fusion protein system; immune-complex in vitro kinase assays; Western blot for MEK and ERK activation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with direct comparison across all three Raf isoforms, confirmed in both mammalian cells and insect cells with epitope-tagged proteins","pmids":["7565795"],"is_preprint":false},{"year":1996,"finding":"A-Raf (and c-Raf) expressed in neonatal rat ventricular myocytes both phosphorylate, activate, and form complexes with MEK1 in vitro; however, A-Raf and c-Raf are differentially regulated by hypertrophic stimuli: TPA produces sustained A-Raf activation, whereas aFGF activates c-Raf but not A-Raf, and cAMP-dependent PKA inhibits c-Raf but not A-Raf.","method":"Immunoprecipitation kinase assays; co-complex formation; pharmacological activation/inhibition in cultured cardiomyocytes","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal immunoprecipitation kinase assay plus multiple pharmacological perturbations, single lab","pmids":["7592840"],"is_preprint":false},{"year":1996,"finding":"A-Raf selectively phosphorylates and activates MEK1 but not MEK2 in response to EGF stimulation in HeLa cells; yeast two-hybrid using MEK1 S218/222A mutant as bait identified all three Raf family members as interactors, suggesting elimination of phosphorylation sites stabilizes the kinase–substrate interaction.","method":"Yeast two-hybrid; in vitro kinase assay; EGF stimulation of HeLa cells; MEK1/MEK2 phosphorylation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus in vitro kinase assay, single lab","pmids":["8621729"],"is_preprint":false},{"year":1997,"finding":"The regulatory subunit of protein kinase CK2 (CK2β) specifically binds to A-Raf (residues 550–569 in the kinase domain) but not to B-Raf or C-Raf, and co-expression of CK2β with A-Raf in Sf9 cells enhances A-Raf kinase activity ~10-fold; this effect is abolished by the CK2 catalytic α subunit.","method":"Yeast two-hybrid screening; Sf9 co-expression kinase assays; domain mapping","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid confirmed by in vitro kinase activity measurement in insect cells, domain mapped, single lab","pmids":["9042966","9042965"],"is_preprint":false},{"year":1997,"finding":"Mutation of two key tyrosine residues (analogous to activating Asp residues in B-Raf) to aspartic acid in A-Raf's kinase domain (~10-fold increase in catalytic activity) or to phenylalanine (loss of activity) demonstrates that these tyrosines are critical regulatory residues controlling A-Raf catalytic activity; introduction of Asp increases oncogenic transformation, while Phe abolishes it.","method":"Site-directed mutagenesis; Raf:ER fusion protein transformation assays in Rat1/3T3 cells; immune-complex kinase assays; Sf9 insect cell expression","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted mutagenesis in multiple cell systems with in vitro kinase assays and functional transformation readout","pmids":["9285556"],"is_preprint":false},{"year":1999,"finding":"In IL-3-dependent hematopoietic cells, A-Raf (but not B-Raf or c-Raf) is activated downstream of PI3-K, is insensitive to cAMP inhibition, and is required for MEK-ERK activation; dominant-negative A-Raf blocks MEK activation whereas dominant-negative c-Raf does not, establishing A-Raf as the primary Raf isoform coupling PI3-K signals to MEK in these cells.","method":"PI3-K inhibitor (wortmannin/LY294002); cAMP elevation; dominant-negative isoform overexpression; immunoprecipitation kinase assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via dominant-negatives plus pharmacological inhibition, single lab with multiple orthogonal approaches","pmids":["10066754"],"is_preprint":false},{"year":2000,"finding":"A-RAF localizes specifically to mitochondria in rat liver cells (determined by Western blot and immunogold labeling of purified mitochondria), and two novel human mitochondrial import receptor proteins (hTOM and hTIM, related to TOM/TIM translocase components) interact specifically with A-RAF; 14-3-3, which interacts with C-RAF, does not bind A-RAF's N-terminal domain.","method":"Western blot of purified mitochondrial fractions; immunogold electron microscopy; yeast two-hybrid; protein interaction studies","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular fractionation with immunogold EM confirmation plus protein interaction identification, single lab","pmids":["10848612"],"is_preprint":false},{"year":2000,"finding":"A-Raf associates with the p85 subunit of PI3-kinase through a phosphotyrosine-independent SH2 domain interaction requiring basic residues (part of the sequence LQRIRS) in A-Raf; this complex exists in both quiescent and growth factor-stimulated cells and can be reconstituted by direct in vitro binding.","method":"Phage display peptide library; co-immunoprecipitation; in vitro direct binding assay; mutagenesis of basic residues","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phage display plus in vitro direct binding and mutagenesis, single lab","pmids":["10967104"],"is_preprint":false},{"year":2002,"finding":"A-Raf-deficient mouse embryonic fibroblasts and ES cells show no defects in ERK activation, proliferation, differentiation, apoptosis, or transformation by oncogenic Ras or Src; B-Raf and Raf-1 activities toward MEK are both significantly increased in A-Raf-deficient MEFs, suggesting compensatory upregulation.","method":"Gene-targeted A-Raf knockout MEFs and ES cells; ERK activation assays; transformation assays; immunoprecipitation kinase assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with multiple orthogonal functional readouts; negative result for ERK/MEK role is well-established","pmids":["11821947"],"is_preprint":false},{"year":2003,"finding":"A-Raf prevents cancer cell apoptosis by sequestering and inactivating the pro-apoptotic MST2 kinase; siRNA knockdown of A-Raf results in MST2-dependent apoptosis, and enforced A-Raf expression counteracts etoposide-induced apoptosis; this anti-apoptotic function requires expression of the splicing factor hnRNP H for correct A-Raf transcription.","method":"siRNA knockdown; apoptosis assays; enforced expression; epistasis with MST2","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with defined phenotype and pathway placement via MST2 epistasis, single lab","pmids":["20145135"],"is_preprint":false},{"year":2005,"finding":"A-Raf and Raf-1 have a combined role in controlling transient (but not sustained) ERK/MEK phosphorylation and G1/S cell cycle progression; double knockout (A-Raf/Raf-1) MEFs show delayed S-phase entry, reduced transient MEK/ERK phosphorylation, and reduced c-Fos and cyclin D1 expression, while single knockouts are unaffected.","method":"Double knockout mouse embryonic fibroblasts; cell cycle analysis; Western blot for phospho-MEK/ERK; Ki67 staining","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double-knockout with multiple orthogonal functional readouts demonstrating epistatic redundancy","pmids":["15856007"],"is_preprint":false},{"year":2005,"finding":"A-Raf binds to phosphoinositides including PI(3)P, PI(4)P, PI(5)P, PI(3,5)P2, PI(4,5)P2, PI(3,4)P2, and PA; mutagenesis of two basic residues K50 and R52 in the Ras-binding domain abolishes PI(4,5)P2 binding, suggesting these residues are the PI(4,5)P2 binding site; a second phosphoinositide binding region resides between residues 200–606.","method":"Lipid binding assays; site-directed mutagenesis (K50, R52); deletion mutant analysis","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro lipid binding with mutagenesis, single lab","pmids":["15736953"],"is_preprint":false},{"year":2007,"finding":"A-Raf interacts with and regulates pyruvate kinase M2 (M2-PK): in primary mouse fibroblasts, A-Raf induces M2-PK dimerization (inactive form) reducing glycolysis, whereas oncogenic A-Raf in NIH3T3 cells increases the tetrameric (active) form of M2-PK promoting glycolytic energy production.","method":"Co-immunoprecipitation; enzyme activity assays; glycolysis measurements; primary vs. immortalized fibroblasts comparison","journal":"Anticancer research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-IP with metabolic assay, single lab, limited mechanistic detail in abstract","pmids":["18225557"],"is_preprint":false},{"year":2007,"finding":"The N-region of A-RAF (specifically residues including Y296 and G300) determines its low basal kinase activity and limited inducibility; substitution Y296R in A-RAF yields constitutively active kinase, while G300S (mimicking B-/C-RAF) is inhibitory; conversely, S339G in C-RAF (mimicking A-RAF) creates constitutively active C-RAF, implicating a conserved N-region residue (S339 in C-RAF/R398 interaction) as an inhibitory constraint.","method":"Site-directed mutagenesis; kinase activity assays; molecular modeling based on B-RAF crystal structure","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro mutagenesis with kinase activity assays, single lab; modeling supports but not independently validated","pmids":["17613527"],"is_preprint":false},{"year":2008,"finding":"Mass spectrometry identified multiple novel in vivo phosphorylation sites in A-RAF; Ser-432 participates in MEK binding and is indispensable for A-RAF signaling; an isoform-specific hinge segment (IH-segment, residues 248–267) containing Ser-257, Ser-262, and Ser-264 positively regulates A-RAF activation; phosphorylation within the activation segment does not contribute to EGF-mediated activation.","method":"Mass spectrometry; site-directed mutagenesis; in vitro kinase assays; EGF stimulation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mass spectrometry plus mutagenesis with functional kinase readout, single lab","pmids":["18662992"],"is_preprint":false},{"year":2009,"finding":"A-RAF kinase function in ARF6-regulated endocytic membrane traffic: an N-terminal A-RAF fragment (AR149, corresponding to splice variant DA-RAF2) co-localizes with ARF6 on tubular endosomes and exerts dominant-negative effects on endocytic recycling (not internalization); A-RAF-mediated ERK activation via MEK is required for ARF6-dependent recycling to the recycling compartment.","method":"Co-localization microscopy; dominant-negative expression; endocytic trafficking assays; A-RAF depletion; MEK-ERK pathway inhibition","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular localization with functional consequence demonstrated via dominant-negative and depletion, single lab","pmids":["19247477"],"is_preprint":false},{"year":2011,"finding":"c-Myc positively controls hnRNP H expression, which in turn regulates A-raf mRNA splicing to produce full-length A-Raf vs. A-Raf(short), a truncated dominant-negative isoform retaining the Ras-binding domain; A-Raf(short) suppresses Ras activation and ERK signaling; full-length A-Raf inhibits MST2-dependent apoptosis, while A-Raf(short) does not regulate MST2.","method":"c-Myc manipulation; hnRNP H expression analysis; RT-PCR for splice isoforms; dominant-negative overexpression; Ras-GTP and ERK activation assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis established via c-Myc → hnRNP H → A-Raf splicing with multiple functional readouts, single lab","pmids":["21512137"],"is_preprint":false},{"year":2012,"finding":"ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers in cells treated with RAF inhibitors; ARAF binds to and is activated by BRAF; ARAF is not functionally redundant with CRAF and cannot substitute for CRAF downstream of RAS; two cancer-associated ARAF mutations inactivate the kinase.","method":"Co-immunoprecipitation; ARAF knockdown/overexpression; RAF inhibitor treatment; kinase activity assays; transformation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with functional epistasis, single lab with multiple complementary assays","pmids":["22926515"],"is_preprint":false},{"year":2013,"finding":"Araf directly phosphorylates Smad2 in the linker region (S253 indispensable) in a MEK/ERK-independent manner, promoting degradation of activated Smad2 and attenuating Nodal/Smad2 signaling; in zebrafish, araf knockdown increases activated Smad2, expands mesendoderm, and causes dorsalization.","method":"In vitro kinase assay; site-directed mutagenesis (S253); zebrafish knockdown; Smad2 phosphorylation and degradation assays; co-immunoprecipitation","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro phosphorylation with mutagenesis of specific substrate residue, validated in vivo in zebrafish with genetic rescue","pmids":["23591895"],"is_preprint":false},{"year":2014,"finding":"ARAF dimerization is required for MAPK pathway activation and cell migration: RAF inhibitors induce ARAF homodimerization; ARAF mutants unable to homodimerize fail to interact with endogenous MEK1 and do not activate MEK1 or ERK1/2; in purified protein solution, all three RAF isoforms compete for binding to MEK1; ARAF knockdown prevents RAF-inhibitor-induced MEK1 and ERK1/2 activation and tumor cell spheroid invasion.","method":"Recombinant protein competition assay; co-immunoprecipitation; dimer-deficient ARAF mutant overexpression; siRNA knockdown; 3D spheroid invasion assay","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro reconstituted protein competition plus mutagenesis of dimer interface with defined cellular phenotype, multiple orthogonal methods","pmids":["25097033"],"is_preprint":false},{"year":2014,"finding":"Compound kinase-domain mutations in ARAF found in LCH create a highly active MAP kinase kinase in vitro and transform mouse embryo fibroblasts; mutant ARAF activity is inhibited by the BRAF inhibitor vemurafenib.","method":"In vitro kinase assay; mouse embryo fibroblast transformation assay; vemurafenib inhibition","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay plus transformation assay, single lab","pmids":["24652991"],"is_preprint":false},{"year":2014,"finding":"ARAF mutations S214C and nearby residues transform immortalized human airway epithelial cells in a sorafenib-sensitive manner, demonstrating these mutations confer oncogenic gain-of-function kinase activity.","method":"Cell transformation assay; sorafenib sensitivity assay; whole-genome sequencing","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transformation assay with drug sensitivity, single lab","pmids":["24569458"],"is_preprint":false},{"year":2014,"finding":"hnRNP A2 regulates A-Raf splicing in hepatocellular carcinoma by reducing production of a short dominant-negative A-Raf isoform and elevating full-length A-Raf transcript, thereby activating the Ras-MAPK-ERK pathway; hnRNP A2 knockdown inhibits ERK1/2 activation by EGF.","method":"siRNA knockdown of hnRNP A2; RT-PCR for A-Raf isoforms; ERK1/2 activation by EGF; overexpression studies; tumor formation assay","journal":"RNA","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA plus functional ERK readout, single lab with multiple cell line validations","pmids":["24572810"],"is_preprint":false},{"year":2015,"finding":"ARAF mutations N217I and G322S in intrahepatic cholangiocarcinoma lead to activation of the MAPK pathway; N217I shows oncogenic potential in vitro (transformation assay).","method":"RNA/exome sequencing; MAPK pathway activation assay; in vitro transformation assay","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay (transformation + pathway activation) for specific mutations, single lab","pmids":["25608663"],"is_preprint":false},{"year":2016,"finding":"Subcellular localization of A-Raf determines its ability to inhibit MST2-mediated apoptosis: in proliferating and tumor cells, A-Raf localizes to mitochondria where it sequesters MST2; during epithelial differentiation, A-Raf re-localizes to the plasma membrane (regulated by KSR2 downregulation), releasing MST2 and rendering cells susceptible to apoptosis.","method":"Confocal immunofluorescence; subcellular fractionation; siRNA knockdown of KSR2; MCF7 differentiation model; apoptosis assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by imaging and fractionation with functional consequence demonstrated via apoptosis assays, single lab","pmids":["26891695"],"is_preprint":false},{"year":2017,"finding":"Alternative polyadenylation (APA) of Araf mRNA switches Araf protein isoforms during microglia activation, impacting production of downstream inflammatory cytokines.","method":"cTag-PAPERCLIP APA profiling; cell-type-specific protein isoform analysis; cytokine production assays in microglia","journal":"Neuron","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel APA mapping method with functional cytokine readout, single lab","pmids":["28910620"],"is_preprint":false},{"year":2018,"finding":"Hypusinated EIF5A1 regulates ARAF translation; ARAF mediates EIF5A1-dependent regulation of trophoblast migration and invasion via the integrin/ERK signaling pathway; ARAF levels are positively correlated with EIF5A1 in recurrent miscarriage villous tissues.","method":"EIF5A1 overexpression/knockdown; ARAF Western blot; trophoblast migration/invasion assays; villous explant culture; EIF5A1K50A hypusination mutant","journal":"Cell death & disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-expression/knockdown study linking ARAF to pathway activation, no direct binding or kinase assay for ARAF–integrin interaction","pmids":["30206208"],"is_preprint":false},{"year":2019,"finding":"The recurrent gain-of-function ARAF mutation S214P (loss of a conserved phosphorylation site) elevates ERK1/2 activity, enhances lymphangiogenic capacity, and causes disassembly of actin skeleton and VE-cadherin junctions in transduced cells; these effects are rescued by MEK inhibitor trametinib; an analogous lymphatic phenotype recreated in zebrafish is also rescued by MEK inhibition.","method":"Lentiviral transduction of ARAF-S214P; ERK1/2 phosphorylation assay; lymphangiogenesis assay; actin/VE-cadherin immunofluorescence; zebrafish morpholino model; trametinib rescue","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal cellular assays plus in vivo zebrafish validation with pharmacological rescue, single lab","pmids":["31263281"],"is_preprint":false},{"year":2020,"finding":"ARAF-mediated resistance to the RAF dimer inhibitor belvarafenib requires both kinase activity and dimerization: ARAF kinase-domain mutations found in resistant melanoma cells and patient ctDNA form active dimers in the presence of belvarafenib; dimer-containing mutant ARAF is active under inhibitor conditions.","method":"Belvarafenib-resistant cell line generation; ctDNA sequencing from patients; ARAF mutant dimerization assays; kinase activity assays; panel of type II RAF inhibitors","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic characterization confirmed in both cell lines and patient samples with kinase and dimerization assays, replicated across multiple RAF inhibitors","pmids":["33953400"],"is_preprint":false},{"year":2020,"finding":"LXH254 (type II RAF inhibitor) preferentially inhibits BRAF and CRAF but largely spares ARAF; ARAF-mediated resistance to LXH254 requires both kinase function and dimerization; in RAS-mutant cells expressing only ARAF, LXH254 paradoxically activates MAPK signaling; loss of ARAF sensitizes RAS-mutant cells to LXH254.","method":"Biochemical kinase profiling; ARAF/BRAF/CRAF ablation (isogenic cell lines); kinase-impaired and dimer-deficient ARAF variants; paradoxical activation assays; xenograft models","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic RAF paralog ablation panel with kinase-dead and dimer-deficient mutants plus in vivo xenograft, multiple orthogonal methods","pmids":["33355204"],"is_preprint":false},{"year":2022,"finding":"ARAF activates RAS in a kinase-independent manner by binding to RAS and displacing the GTPase-activating protein NF1, thereby antagonizing NF1-mediated RAS-GTP hydrolysis, reducing ERK-dependent negative feedback on RAS, and increasing RAS-GTP levels; ARAF amplification in EGFR-mutant lung cancers confers resistance to EGFR inhibitors via this mechanism.","method":"Co-immunoprecipitation of ARAF-RAS-NF1 complexes; RAS-GTP pull-down; kinase-dead ARAF expression; ARAF overexpression/depletion; EGFR inhibitor resistance assays; combination with SHP2 inhibitor","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic dissection with kinase-dead mutant, direct protein interaction assays, and functional rescue, single lab with multiple orthogonal methods","pmids":["35613620"],"is_preprint":false},{"year":2022,"finding":"CRAF:ARAF heterodimers are increased in KRAS-mutant cells (quantitative proteomics); depletion of both CRAF and ARAF rescues CRAF-loss phenotype; kinase-dead but not dimer-defective CRAF rescues growth, indicating that CRAF dimerization (including with ARAF) rather than kinase activity is required for maintaining appropriate MAPK signal intensity in KRAS-mutant tumors.","method":"Quantitative proteomics; siRNA depletion; rescue with kinase-dead and dimer-defective mutants; MAPK signaling assays; low-dose MEK/ERK inhibitor rescue","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative proteomics plus genetic rescue with structure-function mutants, single lab","pmids":["35139374"],"is_preprint":false},{"year":2022,"finding":"ARAF suppresses ERBB3 expression in a kinase-independent manner by inhibiting ERBB3 promoter activity through the transcription factor KLF5; ARAF depletion increases ERBB3-AKT signaling and promotes metastasis; reconstitution of ARAF in ARAF-depleted cells reverses enhanced ERBB3-AKT signaling.","method":"ARAF siRNA depletion; ERBB3 promoter reporter assay; AKT signaling assays; KLF5 identification; rescue experiments","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter assay plus kinase-independent rescue with transcription factor pathway placement, single lab","pmids":["35302851"],"is_preprint":false},{"year":2003,"finding":"Trihydrophobin 1 (TH1) specifically binds to A-Raf kinase (but not B-Raf or C-Raf) both in vitro and in vivo; TH1 inhibits A-Raf kinase activity but does not affect B-Raf or C-Raf kinase activity; the A-Raf binding region of TH1 maps to amino acids 1–372; A-Raf kinase activity promotes binding to TH1.","method":"Co-immunoprecipitation; in vitro binding; Raf kinase assay; confocal colocalization; stable transfection with cell cycle analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro binding plus kinase assay with domain mapping, single lab","pmids":["14684750"],"is_preprint":false},{"year":2004,"finding":"A-Raf associates with activated EGF receptor complexes and with PDGF receptor (PDGFR) complexes independently of prior PDGF treatment; expression of partially activated A-Raf mutant decreases tyrosine phosphorylation of PDGFR on Y857 and Y1021 (but not other docking sites) and alters PLCγ1 and PI3K activation.","method":"Co-immunoprecipitation; phospho-specific Western blotting of PDGFR tyrosines; A-Raf mutant overexpression; PLCγ1 and PI3K activity assays","journal":"Cellular signalling","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-IP with downstream signaling readouts, limited mechanistic depth in abstract, single lab","pmids":["15763428"],"is_preprint":false}],"current_model":"ARAF is a serine/threonine kinase with intrinsically lower MEK kinase activity than BRAF or CRAF, regulated by isoform-specific phosphorylations (including an IH-segment and key N-region residues), that participates in the RAS–RAF–MEK–ERK cascade through multiple mechanisms: it can selectively activate MEK1 (but not MEK2) downstream of growth factor receptors, dimerizes (homo- and hetero-) to activate MEK1/ERK in a dimerization-dependent manner, scaffolds BRAF:CRAF heterodimers, directly phosphorylates Smad2 in a MEK-independent manner to attenuate TGF-β/Nodal signaling, sequesters and inactivates pro-apoptotic MST2 kinase (independent of its kinase activity), and activates RAS in a kinase-independent manner by displacing the GTPase-activating protein NF1; its subcellular localization (mitochondria vs. plasma membrane, regulated by KSR2) controls its anti-apoptotic vs. pro-apoptotic state, alternative splicing produces a dominant-negative short isoform that suppresses RAS-ERK signaling, and kinase-domain mutations can confer oncogenic gain-of-function or resistance to RAF dimer inhibitors."},"narrative":{"mechanistic_narrative":"ARAF is a serine/threonine kinase of the RAF family that functions in the RAS–RAF–MEK–ERK cascade but possesses intrinsically lower MEK kinase activity than BRAF or CRAF, phosphorylating MEK1 hundreds-fold less efficiently in vitro [PMID:7565795]. This low basal activity is set by isoform-specific N-region constraints, where residues such as Y296 and G300 restrain catalytic output and engineered substitutions can render the kinase constitutively active [PMID:17613527], with additional positive regulation supplied by an isoform-specific hinge segment and a MEK-binding serine (S432) identified by phosphosite mapping [PMID:18662992]. ARAF selectively activates MEK1 but not MEK2 downstream of growth factor receptors [PMID:8621729], and its activation is dimerization-dependent: it homo- and heterodimerizes, and dimer-deficient mutants fail to bind MEK1 or activate ERK [PMID:25097033]. Genetic loss-of-function studies show ARAF is largely dispensable alone—knockout MEFs retain normal ERK signaling with compensatory BRAF/CRAF upregulation [PMID:11821947]—but ARAF and RAF-1 act redundantly to drive transient MEK/ERK phosphorylation and G1/S progression [PMID:15856007], and ARAF scaffolds and stabilizes BRAF:CRAF heterodimers [PMID:22926515]. Beyond canonical kinase signaling, ARAF carries out several kinase-independent functions: it sequesters and inactivates the pro-apoptotic kinase MST2 to block apoptosis, a function gated by mitochondrial versus plasma-membrane localization controlled by KSR2 [PMID:20145135, PMID:26891695]; it activates RAS by binding RAS and displacing the GAP NF1 to raise RAS-GTP [PMID:35613620]; and it suppresses ERBB3 transcription via KLF5 [PMID:35302851]. ARAF also directly phosphorylates Smad2 in its linker region (S253) in a MEK/ERK-independent manner to attenuate Nodal/Smad2 signaling during development [PMID:23591895]. Alternative splicing produces a truncated dominant-negative isoform that retains the RAS-binding domain and suppresses RAS-ERK signaling, regulated by hnRNP H, hnRNP A2 and c-Myc [PMID:21512137, PMID:24572810]. Recurrent gain-of-function kinase-domain mutations (e.g. S214P/S214C, N217I) drive oncogenic MAPK activation and a lymphatic/lymphangiogenic phenotype rescued by MEK inhibition [PMID:24569458, PMID:31263281], and ARAF kinase-domain mutations confer resistance to type II RAF dimer inhibitors in a manner requiring both kinase activity and dimerization [PMID:33953400, PMID:33355204].","teleology":[{"year":1995,"claim":"Established that ARAF is a functional RAF kinase but quantitatively the weakest activator of MEK, defining the central puzzle of its distinct regulation.","evidence":"Inducible Raf:ER fusion system with direct in vitro kinase comparison across all three RAF isoforms","pmids":["7565795"],"confidence":"High","gaps":["Did not explain the structural basis of low activity","Did not identify ARAF-specific substrates beyond MEK"]},{"year":1996,"claim":"Defined ARAF as a MEK1-selective kinase coupled to specific receptor and second-messenger inputs distinct from c-Raf, showing isoform specialization at the substrate and regulatory level.","evidence":"Yeast two-hybrid, in vitro kinase assays, and pharmacological perturbation in HeLa and cardiomyocytes","pmids":["8621729","7592840"],"confidence":"Medium","gaps":["MEK1 vs MEK2 selectivity mechanism not structurally resolved","Single-lab biochemical readouts"]},{"year":1997,"claim":"Identified the kinase-domain regulatory residues and CK2β as activity modulators, beginning to explain how ARAF catalytic output is constrained and tuned.","evidence":"Site-directed mutagenesis with transformation/kinase readouts; yeast two-hybrid and Sf9 co-expression kinase assays","pmids":["9285556","9042966","9042965"],"confidence":"High","gaps":["In vivo relevance of CK2β regulation not established","Physiological phosphorylation state of the regulatory residues unmapped"]},{"year":1999,"claim":"Placed ARAF as the primary Raf coupling PI3-K to MEK-ERK in hematopoietic cells, distinguishing its upstream wiring from BRAF/CRAF.","evidence":"PI3-K inhibitors, dominant-negative isoforms, and IP kinase assays in IL-3-dependent cells","pmids":["10066754"],"confidence":"Medium","gaps":["Molecular basis of PI3-K-to-ARAF coupling not defined here","Cell-type generality unknown"]},{"year":2000,"claim":"Revealed ARAF subcellular targeting (mitochondria) and a phosphotyrosine-independent association with PI3-kinase p85, hinting at non-canonical localization and binding modes.","evidence":"Mitochondrial fractionation with immunogold EM; phage display, co-IP and in vitro binding for p85","pmids":["10848612","10967104"],"confidence":"Medium","gaps":["Functional consequence of mitochondrial localization unresolved at this stage","hTOM/hTIM interactions not functionally validated"]},{"year":2002,"claim":"Showed ARAF is dispensable for ERK signaling alone due to BRAF/CRAF compensation, reframing its role as specialized or redundant rather than essential to the core cascade.","evidence":"Gene-targeted ARAF knockout MEFs and ES cells with functional readouts","pmids":["11821947"],"confidence":"High","gaps":["Did not test combined RAF loss","Tissue-specific or non-ERK roles not addressed"]},{"year":2003,"claim":"Identified the first kinase-independent anti-apoptotic role of ARAF via MST2 sequestration and an ARAF-specific inhibitor TH1, opening non-canonical signaling functions.","evidence":"siRNA knockdown with MST2 epistasis and apoptosis assays; co-IP and kinase assays for TH1 binding","pmids":["20145135","14684750"],"confidence":"Medium","gaps":["Structural basis of MST2 sequestration unresolved","Single-lab findings"]},{"year":2005,"claim":"Demonstrated functional redundancy of ARAF with RAF-1 in driving transient ERK signaling and cell cycle entry, resolving the discrepancy with the single-knockout phenotype.","evidence":"ARAF/RAF-1 double-knockout MEFs with cell cycle and phospho-MEK/ERK analysis; lipid binding assays","pmids":["15856007","15736953"],"confidence":"High","gaps":["Mechanism of selectivity for transient vs sustained ERK unclear","Physiological role of phosphoinositide binding not established"]},{"year":2007,"claim":"Mapped the N-region residues that impose ARAF's low basal activity, providing a structural rationale for its weak kinase output relative to other RAFs.","evidence":"Site-directed mutagenesis with kinase assays and modeling from BRAF structure; co-IP metabolic studies for M2-PK","pmids":["17613527","18225557"],"confidence":"Medium","gaps":["No crystal structure of ARAF kinase domain","M2-PK interaction is low-confidence and mechanistically thin"]},{"year":2008,"claim":"Defined in vivo ARAF phosphosites controlling MEK binding (S432) and activation (IH-segment), refining the activation logic of the kinase.","evidence":"Mass spectrometry plus mutagenesis with in vitro kinase assays and EGF stimulation","pmids":["18662992"],"confidence":"Medium","gaps":["Kinases responsible for these phosphorylations not identified","Single-lab phosphosite mapping"]},{"year":2011,"claim":"Established that c-Myc/hnRNP H-controlled splicing produces a dominant-negative ARAF(short) that suppresses RAS-ERK, linking isoform choice to pathway output.","evidence":"c-Myc and hnRNP H manipulation, splice-isoform RT-PCR, and RAS-GTP/ERK assays","pmids":["21512137"],"confidence":"Medium","gaps":["Physiological triggers of splicing switch in vivo unclear","Quantitative isoform ratios in tissues not defined"]},{"year":2012,"claim":"Showed ARAF is not redundant with CRAF and scaffolds BRAF:CRAF heterodimers under RAF inhibitor conditions, defining a structural role distinct from catalysis.","evidence":"Co-IP, knockdown/overexpression, RAF inhibitor treatment, and transformation assays","pmids":["22926515"],"confidence":"Medium","gaps":["Dimer interface stoichiometry not fully resolved","Endogenous relevance vs overexpression unclear"]},{"year":2013,"claim":"Identified Smad2 as a direct MEK-independent ARAF substrate, establishing a developmental signaling role outside the canonical MAPK cascade.","evidence":"In vitro kinase assay with S253 mutagenesis and zebrafish knockdown with rescue","pmids":["23591895"],"confidence":"High","gaps":["Regulation of ARAF-Smad2 activity in mammalian development not mapped","Crosstalk with MEK-ERK substrate selection unresolved"]},{"year":2014,"claim":"Demonstrated that ARAF activation strictly requires dimerization, unifying its inhibitor-induced and growth-factor-driven activation with a shared mechanistic requirement.","evidence":"Recombinant protein competition, dimer-deficient mutants, siRNA, and 3D spheroid invasion assays","pmids":["25097033"],"confidence":"High","gaps":["Identity of obligate dimer partners in vivo not fully defined","Dimer-specific conformational change not structurally captured"]},{"year":2014,"claim":"Identified recurrent oncogenic ARAF kinase-domain mutations in LCH, lung, and other cancers that produce hyperactive, drug-targetable MAPK kinases.","evidence":"In vitro kinase and transformation assays with vemurafenib/sorafenib sensitivity; whole-genome sequencing","pmids":["24652991","24569458"],"confidence":"Medium","gaps":["Mutation-specific mechanism of activation not fully resolved","Clinical response durability not addressed"]},{"year":2014,"claim":"Showed hnRNP A2-driven splicing reduces dominant-negative ARAF and activates RAS-MAPK in hepatocellular carcinoma, reinforcing splicing as an oncogenic switch.","evidence":"hnRNP A2 siRNA, splice-isoform RT-PCR, EGF-induced ERK assays, and tumor formation","pmids":["24572810"],"confidence":"Medium","gaps":["Generality across tumor types not tested","Direct hnRNP A2 binding sites on Araf pre-mRNA not mapped"]},{"year":2015,"claim":"Confirmed additional oncogenic ARAF mutations (N217I, G322S) drive MAPK activation in cholangiocarcinoma, extending the mutational spectrum.","evidence":"RNA/exome sequencing with MAPK activation and transformation assays","pmids":["25608663"],"confidence":"Medium","gaps":["Differential potency of mutations not benchmarked","Therapeutic implications not tested in vivo"]},{"year":2016,"claim":"Showed localization (mitochondria vs plasma membrane, set by KSR2) determines whether ARAF blocks or permits MST2-mediated apoptosis, linking spatial control to cell fate.","evidence":"Confocal imaging, fractionation, KSR2 knockdown, and apoptosis assays in a differentiation model","pmids":["26891695"],"confidence":"Medium","gaps":["Mechanism of KSR2-controlled relocalization not defined","In vivo relevance during tissue differentiation untested"]},{"year":2019,"claim":"Defined the recurrent S214P gain-of-function mutation as a cause of lymphatic anomalies driven by ERK hyperactivation and reversible by MEK inhibition, establishing a disease-relevant mechanism.","evidence":"Lentiviral expression, ERK/lymphangiogenesis/junction assays, zebrafish model, and trametinib rescue","pmids":["31263281"],"confidence":"High","gaps":["Why S214 loss is specifically activating not structurally resolved","Endothelial-specific cofactors not identified"]},{"year":2020,"claim":"Established ARAF as a clinically important driver of resistance to type II RAF dimer inhibitors, requiring both kinase activity and dimerization, and showing ARAF can paradoxically maintain MAPK signaling under inhibition.","evidence":"Resistant cell lines, patient ctDNA sequencing, dimerization/kinase mutants, and xenografts across multiple RAF inhibitors","pmids":["33953400","33355204"],"confidence":"High","gaps":["Strategies to co-target ARAF dimers not validated clinically","Why ARAF is spared by these inhibitors structurally not fully defined"]},{"year":2022,"claim":"Uncovered kinase-independent ARAF functions—RAS activation via NF1 displacement and ERBB3 suppression via KLF5—that broaden its role beyond a MEK kinase and explain inhibitor and EGFR-therapy resistance.","evidence":"Co-IP of ARAF-RAS-NF1 complexes, RAS-GTP pull-downs, kinase-dead mutants, promoter reporters, and rescue experiments","pmids":["35613620","35302851","35139374"],"confidence":"High","gaps":["Structural basis of NF1 displacement not solved","Balance between ARAF's kinase and scaffold functions in tumors unclear"]},{"year":null,"claim":"How ARAF's multiple kinase-dependent and kinase-independent activities are integrated and spatially partitioned within a single cell, and whether its non-canonical functions are therapeutically separable, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of full-length ARAF or its dimers","Unknown how localization, splicing, and partner choice are co-regulated","Relative contribution of kinase vs scaffold roles in disease undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,18]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,4,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,30,31]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[11]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[6,24]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[11,24]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,19,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[27,28,30]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9,24]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[10]}],"complexes":["BRAF:CRAF heterodimer","ARAF-RAS-NF1 complex"],"partners":["MEK1","BRAF","CRAF","MST2","NF1","RAS","SMAD2","KSR2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P10398","full_name":"Serine/threonine-protein kinase A-Raf","aliases":["Proto-oncogene A-Raf","Proto-oncogene A-Raf-1","Proto-oncogene Pks"],"length_aa":606,"mass_kda":67.6,"function":"Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May also regulate the TOR signaling cascade. Phosphorylates PFKFB2 (PubMed:36402789) Serves as a positive regulator of myogenic differentiation by inducing cell cycle arrest, the expression of myogenin and other muscle-specific proteins, and myotube formation","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P10398/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARAF","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000078061","cell_line_id":"CID001126","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"RAF1","stoichiometry":10.0},{"gene":"YWHAB","stoichiometry":0.2},{"gene":"YWHAG","stoichiometry":0.2},{"gene":"YWHAH","stoichiometry":0.2},{"gene":"YWHAZ","stoichiometry":0.2},{"gene":"CDC37","stoichiometry":0.2},{"gene":"KDSR","stoichiometry":0.2},{"gene":"MAP2K1","stoichiometry":0.2},{"gene":"MAP2K2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001126","total_profiled":1310},"omim":[{"mim_id":"313440","title":"SYNAPSIN I; SYN1","url":"https://www.omim.org/entry/313440"},{"mim_id":"311010","title":"ARAF PROTOONCOGENE, SERINE/THREONINE KINASE; ARAF","url":"https://www.omim.org/entry/311010"},{"mim_id":"305370","title":"TISSUE INHIBITOR OF METALLOPROTEINASE 1; TIMP1","url":"https://www.omim.org/entry/305370"},{"mim_id":"164757","title":"B-RAF PROTOONCOGENE, SERINE/THREONINE KINASE; BRAF","url":"https://www.omim.org/entry/164757"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ARAF"},"hgnc":{"alias_symbol":["A-Raf"],"prev_symbol":["ARAF1"]},"alphafold":{"accession":"P10398","domains":[{"cath_id":"3.10.20.90","chopping":"19-89","consensus_level":"high","plddt":83.4677,"start":19,"end":89},{"cath_id":"3.30.60.20","chopping":"100-138","consensus_level":"high","plddt":87.7913,"start":100,"end":138},{"cath_id":"1.10.510.10","chopping":"301-459_466-572","consensus_level":"medium","plddt":88.5717,"start":301,"end":572}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10398","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10398-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10398-F1-predicted_aligned_error_v6.png","plddt_mean":70.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARAF","jax_strain_url":"https://www.jax.org/strain/search?query=ARAF"},"sequence":{"accession":"P10398","fasta_url":"https://rest.uniprot.org/uniprotkb/P10398.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10398/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10398"}},"corpus_meta":[{"pmid":"20823850","id":"PMC_20823850","title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20823850","citation_count":1433,"is_preprint":false},{"pmid":"21156289","id":"PMC_21156289","title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.","date":"2010","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/21156289","citation_count":1032,"is_preprint":false},{"pmid":"25608663","id":"PMC_25608663","title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25608663","citation_count":249,"is_preprint":false},{"pmid":"20007444","id":"PMC_20007444","title":"A Raf-like MAPKKK gene DSM1 mediates drought resistance through reactive oxygen species scavenging in rice.","date":"2009","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20007444","citation_count":244,"is_preprint":false},{"pmid":"14688025","id":"PMC_14688025","title":"Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.","date":"2003","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/14688025","citation_count":226,"is_preprint":false},{"pmid":"21441910","id":"PMC_21441910","title":"A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21441910","citation_count":211,"is_preprint":false},{"pmid":"32001690","id":"PMC_32001690","title":"A RAF-SnRK2 kinase cascade mediates early osmotic stress signaling in higher plants.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32001690","citation_count":207,"is_preprint":false},{"pmid":"7565795","id":"PMC_7565795","title":"Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7565795","citation_count":198,"is_preprint":false},{"pmid":"31263281","id":"PMC_31263281","title":"ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.","date":"2019","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31263281","citation_count":162,"is_preprint":false},{"pmid":"9814705","id":"PMC_9814705","title":"CNK, a RAF-binding multidomain protein required for RAS signaling.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9814705","citation_count":149,"is_preprint":false},{"pmid":"3029685","id":"PMC_3029685","title":"The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus.","date":"1987","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/3029685","citation_count":149,"is_preprint":false},{"pmid":"7592840","id":"PMC_7592840","title":"Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7592840","citation_count":143,"is_preprint":false},{"pmid":"4009794","id":"PMC_4009794","title":"Rapid induction of hemopoietic neoplasms in newborn mice by a raf(mil)/myc recombinant murine retrovirus.","date":"1985","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/4009794","citation_count":143,"is_preprint":false},{"pmid":"24652991","id":"PMC_24652991","title":"Somatic activating ARAF mutations in Langerhans cell histiocytosis.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24652991","citation_count":140,"is_preprint":false},{"pmid":"11768610","id":"PMC_11768610","title":"Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells.","date":"2001","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11768610","citation_count":133,"is_preprint":false},{"pmid":"8523586","id":"PMC_8523586","title":"Hepatitis B virus pX activates NF-kappa B-dependent transcription through a Raf-independent pathway.","date":"1996","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8523586","citation_count":129,"is_preprint":false},{"pmid":"8805280","id":"PMC_8805280","title":"Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene.","date":"1996","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/8805280","citation_count":125,"is_preprint":false},{"pmid":"22207574","id":"PMC_22207574","title":"Increased leaf angle1, a Raf-like MAPKKK that interacts with a nuclear protein family, regulates mechanical tissue formation in the Lamina joint of rice.","date":"2011","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/22207574","citation_count":115,"is_preprint":false},{"pmid":"3491291","id":"PMC_3491291","title":"Characterization of murine A-raf, a new oncogene related to the v-raf oncogene.","date":"1986","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3491291","citation_count":114,"is_preprint":false},{"pmid":"8621729","id":"PMC_8621729","title":"Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8621729","citation_count":107,"is_preprint":false},{"pmid":"2847163","id":"PMC_2847163","title":"In vitro-derived leukemic erythroid cell lines induced by a raf- and myc-containing retrovirus differentiate in response to erythropoietin.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2847163","citation_count":105,"is_preprint":false},{"pmid":"33953400","id":"PMC_33953400","title":"ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33953400","citation_count":104,"is_preprint":false},{"pmid":"24416731","id":"PMC_24416731","title":"Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.","date":"2014","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/24416731","citation_count":102,"is_preprint":false},{"pmid":"14973284","id":"PMC_14973284","title":"A Raf/MEK/ERK signaling pathway is required for development of the sea urchin embryo micromere lineage through phosphorylation of the transcription factor Ets.","date":"2004","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14973284","citation_count":100,"is_preprint":false},{"pmid":"9228072","id":"PMC_9228072","title":"A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9228072","citation_count":100,"is_preprint":false},{"pmid":"24569458","id":"PMC_24569458","title":"Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24569458","citation_count":99,"is_preprint":false},{"pmid":"24572810","id":"PMC_24572810","title":"Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.","date":"2014","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24572810","citation_count":88,"is_preprint":false},{"pmid":"9042965","id":"PMC_9042965","title":"A-Raf kinase is a new interacting partner of protein kinase CK2 beta subunit.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9042965","citation_count":87,"is_preprint":false},{"pmid":"2994056","id":"PMC_2994056","title":"Detection of a raf-related and two other transforming DNA sequences in human tumors maintained in nude mice.","date":"1985","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2994056","citation_count":79,"is_preprint":false},{"pmid":"21831957","id":"PMC_21831957","title":"Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21831957","citation_count":78,"is_preprint":false},{"pmid":"7592658","id":"PMC_7592658","title":"Insulin activates nuclear factor kappa B in mammalian cells through a Raf-1-mediated pathway.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7592658","citation_count":78,"is_preprint":false},{"pmid":"9042966","id":"PMC_9042966","title":"The regulatory subunit of protein kinase CK2 is a specific A-Raf activator.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9042966","citation_count":76,"is_preprint":false},{"pmid":"9285556","id":"PMC_9285556","title":"Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9285556","citation_count":75,"is_preprint":false},{"pmid":"33355204","id":"PMC_33355204","title":"LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33355204","citation_count":74,"is_preprint":false},{"pmid":"8955173","id":"PMC_8955173","title":"Activation of nuclear factor-kappaB via T cell receptor requires a Raf kinase and Ca2+ influx. Functional synergy between Raf and calcineurin.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8955173","citation_count":70,"is_preprint":false},{"pmid":"11439028","id":"PMC_11439028","title":"Crystal structures of YBHB and YBCL from Escherichia coli, two bacterial homologues to a Raf kinase inhibitor protein.","date":"2001","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11439028","citation_count":70,"is_preprint":false},{"pmid":"15956248","id":"PMC_15956248","title":"ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells.","date":"2005","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15956248","citation_count":68,"is_preprint":false},{"pmid":"27834212","id":"PMC_27834212","title":"Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27834212","citation_count":67,"is_preprint":false},{"pmid":"20145135","id":"PMC_20145135","title":"Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20145135","citation_count":67,"is_preprint":false},{"pmid":"10066754","id":"PMC_10066754","title":"A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10066754","citation_count":65,"is_preprint":false},{"pmid":"32814086","id":"PMC_32814086","title":"Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK signaling pathway.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32814086","citation_count":65,"is_preprint":false},{"pmid":"28358053","id":"PMC_28358053","title":"A Raf-like protein kinase BHP mediates blue light-dependent stomatal opening.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28358053","citation_count":58,"is_preprint":false},{"pmid":"17085575","id":"PMC_17085575","title":"Glycosylation of Pseudomonas aeruginosa strain Pa5196 type IV pilins with mycobacterium-like alpha-1,5-linked d-Araf oligosaccharides.","date":"2006","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/17085575","citation_count":58,"is_preprint":false},{"pmid":"22926515","id":"PMC_22926515","title":"ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22926515","citation_count":56,"is_preprint":false},{"pmid":"10848612","id":"PMC_10848612","title":"Isoform-specific localization of A-RAF in mitochondria.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10848612","citation_count":56,"is_preprint":false},{"pmid":"14647418","id":"PMC_14647418","title":"Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14647418","citation_count":56,"is_preprint":false},{"pmid":"28910620","id":"PMC_28910620","title":"cTag-PAPERCLIP Reveals Alternative Polyadenylation Promotes Cell-Type Specific Protein Diversity and Shifts Araf Isoforms with Microglia Activation.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28910620","citation_count":55,"is_preprint":false},{"pmid":"17283155","id":"PMC_17283155","title":"Bcl-2 protects endothelial cells against gamma-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17283155","citation_count":55,"is_preprint":false},{"pmid":"27717463","id":"PMC_27717463","title":"A Raf-like MAPKKK gene, GhRaf19, negatively regulates tolerance to drought and salt and positively regulates resistance to cold stress by modulating reactive oxygen species in cotton.","date":"2016","source":"Plant science : an international journal of experimental plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/27717463","citation_count":52,"is_preprint":false},{"pmid":"20424636","id":"PMC_20424636","title":"Blockade of the MEK/ERK pathway with a raf inhibitor prevents activation of pro-inflammatory mediators in cerebral arteries and reduction in cerebral blood flow after subarachnoid hemorrhage in a rat model.","date":"2010","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20424636","citation_count":52,"is_preprint":false},{"pmid":"21512137","id":"PMC_21512137","title":"c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21512137","citation_count":51,"is_preprint":false},{"pmid":"11821947","id":"PMC_11821947","title":"ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11821947","citation_count":51,"is_preprint":false},{"pmid":"32605999","id":"PMC_32605999","title":"KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32605999","citation_count":50,"is_preprint":false},{"pmid":"18805982","id":"PMC_18805982","title":"Modification of Pseudomonas aeruginosa Pa5196 type IV Pilins at multiple sites with D-Araf by a novel GT-C family Arabinosyltransferase, TfpW.","date":"2008","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/18805982","citation_count":47,"is_preprint":false},{"pmid":"25097033","id":"PMC_25097033","title":"Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.","date":"2014","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/25097033","citation_count":46,"is_preprint":false},{"pmid":"27540684","id":"PMC_27540684","title":"PEBP1, a RAF kinase inhibitory protein, negatively regulates starvation-induced autophagy by direct interaction with LC3.","date":"2016","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/27540684","citation_count":45,"is_preprint":false},{"pmid":"12612072","id":"PMC_12612072","title":"A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12612072","citation_count":43,"is_preprint":false},{"pmid":"18225557","id":"PMC_18225557","title":"Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism.","date":"2007","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18225557","citation_count":43,"is_preprint":false},{"pmid":"17967876","id":"PMC_17967876","title":"A-raf and B-raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17967876","citation_count":41,"is_preprint":false},{"pmid":"9058592","id":"PMC_9058592","title":"Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation.","date":"1997","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9058592","citation_count":41,"is_preprint":false},{"pmid":"30206208","id":"PMC_30206208","title":"EIF5A1 promotes trophoblast migration and invasion via ARAF-mediated activation of the integrin/ERK signaling pathway.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30206208","citation_count":37,"is_preprint":false},{"pmid":"7750478","id":"PMC_7750478","title":"The segment-specific pattern of A-raf expression in the mouse epididymis is regulated by testicular factors.","date":"1995","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7750478","citation_count":36,"is_preprint":false},{"pmid":"35139374","id":"PMC_35139374","title":"CRAF dimerization with ARAF regulates KRAS-driven tumor growth.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35139374","citation_count":35,"is_preprint":false},{"pmid":"3529082","id":"PMC_3529082","title":"Pks, a raf-related sequence in humans.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3529082","citation_count":35,"is_preprint":false},{"pmid":"1572636","id":"PMC_1572636","title":"Physical linkage of the A-raf-1, properdin, synapsin I, and TIMP genes on the human and mouse X chromosomes.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1572636","citation_count":35,"is_preprint":false},{"pmid":"15676015","id":"PMC_15676015","title":"Mutational analysis of the ARAF gene in human cancers.","date":"2005","source":"APMIS : acta pathologica, microbiologica, et immunologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/15676015","citation_count":34,"is_preprint":false},{"pmid":"15856007","id":"PMC_15856007","title":"A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15856007","citation_count":32,"is_preprint":false},{"pmid":"18662992","id":"PMC_18662992","title":"Positive regulation of A-RAF by phosphorylation of isoform-specific hinge segment and identification of novel phosphorylation sites.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18662992","citation_count":31,"is_preprint":false},{"pmid":"18328477","id":"PMC_18328477","title":"Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner.","date":"2008","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18328477","citation_count":30,"is_preprint":false},{"pmid":"26508523","id":"PMC_26508523","title":"A-Raf: A new star of the family of raf kinases.","date":"2015","source":"Critical reviews in biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26508523","citation_count":29,"is_preprint":false},{"pmid":"23591895","id":"PMC_23591895","title":"Araf kinase antagonizes Nodal-Smad2 activity in mesendoderm development by directly phosphorylating the Smad2 linker region.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/23591895","citation_count":29,"is_preprint":false},{"pmid":"23242995","id":"PMC_23242995","title":"PKD controls mitotic Golgi complex fragmentation through a Raf-MEK1 pathway.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/23242995","citation_count":29,"is_preprint":false},{"pmid":"17613527","id":"PMC_17613527","title":"Unique N-region determines low basal activity and limited inducibility of A-RAF kinase: the role of N-region in the evolutionary divergence of RAF kinase function in vertebrates.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17613527","citation_count":29,"is_preprint":false},{"pmid":"33364237","id":"PMC_33364237","title":"Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33364237","citation_count":28,"is_preprint":false},{"pmid":"10768864","id":"PMC_10768864","title":"Expression of the A-raf proto-oncogene in the normal adult and embryonic mouse.","date":"2000","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/10768864","citation_count":26,"is_preprint":false},{"pmid":"25788415","id":"PMC_25788415","title":"Activated k-ras, but not h-ras or N-ras, regulates brain neural stem cell proliferation in a raf/rb-dependent manner.","date":"2015","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/25788415","citation_count":26,"is_preprint":false},{"pmid":"10967104","id":"PMC_10967104","title":"Using a phage display library to identify basic residues in A-Raf required to mediate binding to the Src homology 2 domains of the p85 subunit of phosphatidylinositol 3'-kinase.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10967104","citation_count":26,"is_preprint":false},{"pmid":"1905878","id":"PMC_1905878","title":"A highly polymorphic dinucleotide repeat on the proximal short arm of the human X chromosome: linkage mapping of the synapsin I/A-raf-1 genes.","date":"1991","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1905878","citation_count":26,"is_preprint":false},{"pmid":"35567492","id":"PMC_35567492","title":"A serine-rich effector from the stripe rust pathogen targets a Raf-like kinase to suppress host immunity.","date":"2022","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35567492","citation_count":25,"is_preprint":false},{"pmid":"1406695","id":"PMC_1406695","title":"A Raf-1-related p110 polypeptide associates with the CD4-p56lck complex in T cells.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1406695","citation_count":25,"is_preprint":false},{"pmid":"36142409","id":"PMC_36142409","title":"TTYH3 Modulates Bladder Cancer Proliferation and Metastasis via FGFR1/H-Ras/A-Raf/MEK/ERK Pathway.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36142409","citation_count":22,"is_preprint":false},{"pmid":"15075211","id":"PMC_15075211","title":"Brain-derived neurotrophic factor-, epidermal growth factor-, or A-Raf-induced growth of HaCaT keratinocytes requires extracellular signal-regulated kinase.","date":"2004","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15075211","citation_count":21,"is_preprint":false},{"pmid":"26891695","id":"PMC_26891695","title":"Differential localization of A-Raf regulates MST2-mediated apoptosis during epithelial differentiation.","date":"2016","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26891695","citation_count":20,"is_preprint":false},{"pmid":"8430097","id":"PMC_8430097","title":"Characterization of downstream elements in a Raf-1 pathway.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8430097","citation_count":18,"is_preprint":false},{"pmid":"3299748","id":"PMC_3299748","title":"A-raf oncogene localizes on mouse X chromosome to region some 10-17 centimorgans proximal to hypoxanthine phosphoribosyltransferase gene.","date":"1987","source":"Somatic cell and molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/3299748","citation_count":18,"is_preprint":false},{"pmid":"3449797","id":"PMC_3449797","title":"The complete primary structure of the rat A-raf cDNA coding region: conservation of the putative regulatory regions present in rat c-raf.","date":"1987","source":"Oncogene research","url":"https://pubmed.ncbi.nlm.nih.gov/3449797","citation_count":18,"is_preprint":false},{"pmid":"35613620","id":"PMC_35613620","title":"ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.","date":"2022","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/35613620","citation_count":17,"is_preprint":false},{"pmid":"8020955","id":"PMC_8020955","title":"The complete sequence and promoter activity of the human A-raf-1 gene (ARAF1).","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8020955","citation_count":17,"is_preprint":false},{"pmid":"8622887","id":"PMC_8622887","title":"Regulation of A-raf expression.","date":"1996","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8622887","citation_count":17,"is_preprint":false},{"pmid":"16603190","id":"PMC_16603190","title":"ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells.","date":"2006","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/16603190","citation_count":17,"is_preprint":false},{"pmid":"30324893","id":"PMC_30324893","title":"Elevated Expression of A-Raf and FA2H in Hepatocellular Carcinoma is Associated with Lipid Metabolism Dysregulation and Cancer Progression.","date":"2019","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30324893","citation_count":16,"is_preprint":false},{"pmid":"14684750","id":"PMC_14684750","title":"Trihydrophobin 1 is a new negative regulator of A-Raf kinase.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14684750","citation_count":16,"is_preprint":false},{"pmid":"15736953","id":"PMC_15736953","title":"Identification of key residues in the A-Raf kinase important for phosphoinositide lipid binding specificity.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15736953","citation_count":16,"is_preprint":false},{"pmid":"19247477","id":"PMC_19247477","title":"A-RAF kinase functions in ARF6 regulated endocytic membrane traffic.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19247477","citation_count":15,"is_preprint":false},{"pmid":"16980614","id":"PMC_16980614","title":"Cortical migration defects in mice expressing A-RAF from the B-RAF locus.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16980614","citation_count":14,"is_preprint":false},{"pmid":"30609867","id":"PMC_30609867","title":"α-Ketoglutaric Acid-Modified Carbonate Apatite Enhances Cellular Uptake and Cytotoxicity of a Raf- Kinase Inhibitor in Breast Cancer Cells through Inhibition of MAPK and PI-3 Kinase Pathways.","date":"2019","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/30609867","citation_count":14,"is_preprint":false},{"pmid":"35302851","id":"PMC_35302851","title":"ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35302851","citation_count":13,"is_preprint":false},{"pmid":"15763428","id":"PMC_15763428","title":"A-Raf associates with and regulates platelet-derived growth factor receptor signalling.","date":"2004","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/15763428","citation_count":13,"is_preprint":false},{"pmid":"10850371","id":"PMC_10850371","title":"Identification, by cDNA microarray, of A-raf and proliferating cell nuclear antigen as genes induced in rat lung by exposure to diesel exhaust.","date":"1999","source":"Research communications in molecular pathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10850371","citation_count":13,"is_preprint":false},{"pmid":"32923479","id":"PMC_32923479","title":"Silencing ARAF Suppresses the Malignant Phenotypes of Gallbladder Cancer Cells.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32923479","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48538,"output_tokens":8791,"usd":0.138739,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18594,"output_tokens":6216,"usd":0.124185,"stage2_stop_reason":"end_turn"},"total_usd":0.262924,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"A-Raf kinase domain (deltaA-Raf:ER) activates MEK and ERK upon estradiol-induced activation in mammalian cells, but phosphorylates MEK1 in vitro at least 500-fold less efficiently than deltaB-Raf:ER and ~10-fold less efficiently than deltaRaf-1:ER, demonstrating A-Raf has intrinsically lower MEK kinase activity than the other Raf isoforms.\",\n      \"method\": \"Inducible Raf:ER fusion protein system; immune-complex in vitro kinase assays; Western blot for MEK and ERK activation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with direct comparison across all three Raf isoforms, confirmed in both mammalian cells and insect cells with epitope-tagged proteins\",\n      \"pmids\": [\"7565795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A-Raf (and c-Raf) expressed in neonatal rat ventricular myocytes both phosphorylate, activate, and form complexes with MEK1 in vitro; however, A-Raf and c-Raf are differentially regulated by hypertrophic stimuli: TPA produces sustained A-Raf activation, whereas aFGF activates c-Raf but not A-Raf, and cAMP-dependent PKA inhibits c-Raf but not A-Raf.\",\n      \"method\": \"Immunoprecipitation kinase assays; co-complex formation; pharmacological activation/inhibition in cultured cardiomyocytes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal immunoprecipitation kinase assay plus multiple pharmacological perturbations, single lab\",\n      \"pmids\": [\"7592840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A-Raf selectively phosphorylates and activates MEK1 but not MEK2 in response to EGF stimulation in HeLa cells; yeast two-hybrid using MEK1 S218/222A mutant as bait identified all three Raf family members as interactors, suggesting elimination of phosphorylation sites stabilizes the kinase–substrate interaction.\",\n      \"method\": \"Yeast two-hybrid; in vitro kinase assay; EGF stimulation of HeLa cells; MEK1/MEK2 phosphorylation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus in vitro kinase assay, single lab\",\n      \"pmids\": [\"8621729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The regulatory subunit of protein kinase CK2 (CK2β) specifically binds to A-Raf (residues 550–569 in the kinase domain) but not to B-Raf or C-Raf, and co-expression of CK2β with A-Raf in Sf9 cells enhances A-Raf kinase activity ~10-fold; this effect is abolished by the CK2 catalytic α subunit.\",\n      \"method\": \"Yeast two-hybrid screening; Sf9 co-expression kinase assays; domain mapping\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid confirmed by in vitro kinase activity measurement in insect cells, domain mapped, single lab\",\n      \"pmids\": [\"9042966\", \"9042965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Mutation of two key tyrosine residues (analogous to activating Asp residues in B-Raf) to aspartic acid in A-Raf's kinase domain (~10-fold increase in catalytic activity) or to phenylalanine (loss of activity) demonstrates that these tyrosines are critical regulatory residues controlling A-Raf catalytic activity; introduction of Asp increases oncogenic transformation, while Phe abolishes it.\",\n      \"method\": \"Site-directed mutagenesis; Raf:ER fusion protein transformation assays in Rat1/3T3 cells; immune-complex kinase assays; Sf9 insect cell expression\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted mutagenesis in multiple cell systems with in vitro kinase assays and functional transformation readout\",\n      \"pmids\": [\"9285556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In IL-3-dependent hematopoietic cells, A-Raf (but not B-Raf or c-Raf) is activated downstream of PI3-K, is insensitive to cAMP inhibition, and is required for MEK-ERK activation; dominant-negative A-Raf blocks MEK activation whereas dominant-negative c-Raf does not, establishing A-Raf as the primary Raf isoform coupling PI3-K signals to MEK in these cells.\",\n      \"method\": \"PI3-K inhibitor (wortmannin/LY294002); cAMP elevation; dominant-negative isoform overexpression; immunoprecipitation kinase assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via dominant-negatives plus pharmacological inhibition, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"10066754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A-RAF localizes specifically to mitochondria in rat liver cells (determined by Western blot and immunogold labeling of purified mitochondria), and two novel human mitochondrial import receptor proteins (hTOM and hTIM, related to TOM/TIM translocase components) interact specifically with A-RAF; 14-3-3, which interacts with C-RAF, does not bind A-RAF's N-terminal domain.\",\n      \"method\": \"Western blot of purified mitochondrial fractions; immunogold electron microscopy; yeast two-hybrid; protein interaction studies\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular fractionation with immunogold EM confirmation plus protein interaction identification, single lab\",\n      \"pmids\": [\"10848612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"A-Raf associates with the p85 subunit of PI3-kinase through a phosphotyrosine-independent SH2 domain interaction requiring basic residues (part of the sequence LQRIRS) in A-Raf; this complex exists in both quiescent and growth factor-stimulated cells and can be reconstituted by direct in vitro binding.\",\n      \"method\": \"Phage display peptide library; co-immunoprecipitation; in vitro direct binding assay; mutagenesis of basic residues\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phage display plus in vitro direct binding and mutagenesis, single lab\",\n      \"pmids\": [\"10967104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A-Raf-deficient mouse embryonic fibroblasts and ES cells show no defects in ERK activation, proliferation, differentiation, apoptosis, or transformation by oncogenic Ras or Src; B-Raf and Raf-1 activities toward MEK are both significantly increased in A-Raf-deficient MEFs, suggesting compensatory upregulation.\",\n      \"method\": \"Gene-targeted A-Raf knockout MEFs and ES cells; ERK activation assays; transformation assays; immunoprecipitation kinase assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with multiple orthogonal functional readouts; negative result for ERK/MEK role is well-established\",\n      \"pmids\": [\"11821947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A-Raf prevents cancer cell apoptosis by sequestering and inactivating the pro-apoptotic MST2 kinase; siRNA knockdown of A-Raf results in MST2-dependent apoptosis, and enforced A-Raf expression counteracts etoposide-induced apoptosis; this anti-apoptotic function requires expression of the splicing factor hnRNP H for correct A-Raf transcription.\",\n      \"method\": \"siRNA knockdown; apoptosis assays; enforced expression; epistasis with MST2\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with defined phenotype and pathway placement via MST2 epistasis, single lab\",\n      \"pmids\": [\"20145135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A-Raf and Raf-1 have a combined role in controlling transient (but not sustained) ERK/MEK phosphorylation and G1/S cell cycle progression; double knockout (A-Raf/Raf-1) MEFs show delayed S-phase entry, reduced transient MEK/ERK phosphorylation, and reduced c-Fos and cyclin D1 expression, while single knockouts are unaffected.\",\n      \"method\": \"Double knockout mouse embryonic fibroblasts; cell cycle analysis; Western blot for phospho-MEK/ERK; Ki67 staining\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double-knockout with multiple orthogonal functional readouts demonstrating epistatic redundancy\",\n      \"pmids\": [\"15856007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A-Raf binds to phosphoinositides including PI(3)P, PI(4)P, PI(5)P, PI(3,5)P2, PI(4,5)P2, PI(3,4)P2, and PA; mutagenesis of two basic residues K50 and R52 in the Ras-binding domain abolishes PI(4,5)P2 binding, suggesting these residues are the PI(4,5)P2 binding site; a second phosphoinositide binding region resides between residues 200–606.\",\n      \"method\": \"Lipid binding assays; site-directed mutagenesis (K50, R52); deletion mutant analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro lipid binding with mutagenesis, single lab\",\n      \"pmids\": [\"15736953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A-Raf interacts with and regulates pyruvate kinase M2 (M2-PK): in primary mouse fibroblasts, A-Raf induces M2-PK dimerization (inactive form) reducing glycolysis, whereas oncogenic A-Raf in NIH3T3 cells increases the tetrameric (active) form of M2-PK promoting glycolytic energy production.\",\n      \"method\": \"Co-immunoprecipitation; enzyme activity assays; glycolysis measurements; primary vs. immortalized fibroblasts comparison\",\n      \"journal\": \"Anticancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-IP with metabolic assay, single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"18225557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The N-region of A-RAF (specifically residues including Y296 and G300) determines its low basal kinase activity and limited inducibility; substitution Y296R in A-RAF yields constitutively active kinase, while G300S (mimicking B-/C-RAF) is inhibitory; conversely, S339G in C-RAF (mimicking A-RAF) creates constitutively active C-RAF, implicating a conserved N-region residue (S339 in C-RAF/R398 interaction) as an inhibitory constraint.\",\n      \"method\": \"Site-directed mutagenesis; kinase activity assays; molecular modeling based on B-RAF crystal structure\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro mutagenesis with kinase activity assays, single lab; modeling supports but not independently validated\",\n      \"pmids\": [\"17613527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mass spectrometry identified multiple novel in vivo phosphorylation sites in A-RAF; Ser-432 participates in MEK binding and is indispensable for A-RAF signaling; an isoform-specific hinge segment (IH-segment, residues 248–267) containing Ser-257, Ser-262, and Ser-264 positively regulates A-RAF activation; phosphorylation within the activation segment does not contribute to EGF-mediated activation.\",\n      \"method\": \"Mass spectrometry; site-directed mutagenesis; in vitro kinase assays; EGF stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mass spectrometry plus mutagenesis with functional kinase readout, single lab\",\n      \"pmids\": [\"18662992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A-RAF kinase function in ARF6-regulated endocytic membrane traffic: an N-terminal A-RAF fragment (AR149, corresponding to splice variant DA-RAF2) co-localizes with ARF6 on tubular endosomes and exerts dominant-negative effects on endocytic recycling (not internalization); A-RAF-mediated ERK activation via MEK is required for ARF6-dependent recycling to the recycling compartment.\",\n      \"method\": \"Co-localization microscopy; dominant-negative expression; endocytic trafficking assays; A-RAF depletion; MEK-ERK pathway inhibition\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular localization with functional consequence demonstrated via dominant-negative and depletion, single lab\",\n      \"pmids\": [\"19247477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"c-Myc positively controls hnRNP H expression, which in turn regulates A-raf mRNA splicing to produce full-length A-Raf vs. A-Raf(short), a truncated dominant-negative isoform retaining the Ras-binding domain; A-Raf(short) suppresses Ras activation and ERK signaling; full-length A-Raf inhibits MST2-dependent apoptosis, while A-Raf(short) does not regulate MST2.\",\n      \"method\": \"c-Myc manipulation; hnRNP H expression analysis; RT-PCR for splice isoforms; dominant-negative overexpression; Ras-GTP and ERK activation assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis established via c-Myc → hnRNP H → A-Raf splicing with multiple functional readouts, single lab\",\n      \"pmids\": [\"21512137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers in cells treated with RAF inhibitors; ARAF binds to and is activated by BRAF; ARAF is not functionally redundant with CRAF and cannot substitute for CRAF downstream of RAS; two cancer-associated ARAF mutations inactivate the kinase.\",\n      \"method\": \"Co-immunoprecipitation; ARAF knockdown/overexpression; RAF inhibitor treatment; kinase activity assays; transformation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with functional epistasis, single lab with multiple complementary assays\",\n      \"pmids\": [\"22926515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Araf directly phosphorylates Smad2 in the linker region (S253 indispensable) in a MEK/ERK-independent manner, promoting degradation of activated Smad2 and attenuating Nodal/Smad2 signaling; in zebrafish, araf knockdown increases activated Smad2, expands mesendoderm, and causes dorsalization.\",\n      \"method\": \"In vitro kinase assay; site-directed mutagenesis (S253); zebrafish knockdown; Smad2 phosphorylation and degradation assays; co-immunoprecipitation\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro phosphorylation with mutagenesis of specific substrate residue, validated in vivo in zebrafish with genetic rescue\",\n      \"pmids\": [\"23591895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ARAF dimerization is required for MAPK pathway activation and cell migration: RAF inhibitors induce ARAF homodimerization; ARAF mutants unable to homodimerize fail to interact with endogenous MEK1 and do not activate MEK1 or ERK1/2; in purified protein solution, all three RAF isoforms compete for binding to MEK1; ARAF knockdown prevents RAF-inhibitor-induced MEK1 and ERK1/2 activation and tumor cell spheroid invasion.\",\n      \"method\": \"Recombinant protein competition assay; co-immunoprecipitation; dimer-deficient ARAF mutant overexpression; siRNA knockdown; 3D spheroid invasion assay\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro reconstituted protein competition plus mutagenesis of dimer interface with defined cellular phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"25097033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Compound kinase-domain mutations in ARAF found in LCH create a highly active MAP kinase kinase in vitro and transform mouse embryo fibroblasts; mutant ARAF activity is inhibited by the BRAF inhibitor vemurafenib.\",\n      \"method\": \"In vitro kinase assay; mouse embryo fibroblast transformation assay; vemurafenib inhibition\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay plus transformation assay, single lab\",\n      \"pmids\": [\"24652991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ARAF mutations S214C and nearby residues transform immortalized human airway epithelial cells in a sorafenib-sensitive manner, demonstrating these mutations confer oncogenic gain-of-function kinase activity.\",\n      \"method\": \"Cell transformation assay; sorafenib sensitivity assay; whole-genome sequencing\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transformation assay with drug sensitivity, single lab\",\n      \"pmids\": [\"24569458\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"hnRNP A2 regulates A-Raf splicing in hepatocellular carcinoma by reducing production of a short dominant-negative A-Raf isoform and elevating full-length A-Raf transcript, thereby activating the Ras-MAPK-ERK pathway; hnRNP A2 knockdown inhibits ERK1/2 activation by EGF.\",\n      \"method\": \"siRNA knockdown of hnRNP A2; RT-PCR for A-Raf isoforms; ERK1/2 activation by EGF; overexpression studies; tumor formation assay\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA plus functional ERK readout, single lab with multiple cell line validations\",\n      \"pmids\": [\"24572810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ARAF mutations N217I and G322S in intrahepatic cholangiocarcinoma lead to activation of the MAPK pathway; N217I shows oncogenic potential in vitro (transformation assay).\",\n      \"method\": \"RNA/exome sequencing; MAPK pathway activation assay; in vitro transformation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay (transformation + pathway activation) for specific mutations, single lab\",\n      \"pmids\": [\"25608663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Subcellular localization of A-Raf determines its ability to inhibit MST2-mediated apoptosis: in proliferating and tumor cells, A-Raf localizes to mitochondria where it sequesters MST2; during epithelial differentiation, A-Raf re-localizes to the plasma membrane (regulated by KSR2 downregulation), releasing MST2 and rendering cells susceptible to apoptosis.\",\n      \"method\": \"Confocal immunofluorescence; subcellular fractionation; siRNA knockdown of KSR2; MCF7 differentiation model; apoptosis assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by imaging and fractionation with functional consequence demonstrated via apoptosis assays, single lab\",\n      \"pmids\": [\"26891695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Alternative polyadenylation (APA) of Araf mRNA switches Araf protein isoforms during microglia activation, impacting production of downstream inflammatory cytokines.\",\n      \"method\": \"cTag-PAPERCLIP APA profiling; cell-type-specific protein isoform analysis; cytokine production assays in microglia\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel APA mapping method with functional cytokine readout, single lab\",\n      \"pmids\": [\"28910620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Hypusinated EIF5A1 regulates ARAF translation; ARAF mediates EIF5A1-dependent regulation of trophoblast migration and invasion via the integrin/ERK signaling pathway; ARAF levels are positively correlated with EIF5A1 in recurrent miscarriage villous tissues.\",\n      \"method\": \"EIF5A1 overexpression/knockdown; ARAF Western blot; trophoblast migration/invasion assays; villous explant culture; EIF5A1K50A hypusination mutant\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-expression/knockdown study linking ARAF to pathway activation, no direct binding or kinase assay for ARAF–integrin interaction\",\n      \"pmids\": [\"30206208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The recurrent gain-of-function ARAF mutation S214P (loss of a conserved phosphorylation site) elevates ERK1/2 activity, enhances lymphangiogenic capacity, and causes disassembly of actin skeleton and VE-cadherin junctions in transduced cells; these effects are rescued by MEK inhibitor trametinib; an analogous lymphatic phenotype recreated in zebrafish is also rescued by MEK inhibition.\",\n      \"method\": \"Lentiviral transduction of ARAF-S214P; ERK1/2 phosphorylation assay; lymphangiogenesis assay; actin/VE-cadherin immunofluorescence; zebrafish morpholino model; trametinib rescue\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal cellular assays plus in vivo zebrafish validation with pharmacological rescue, single lab\",\n      \"pmids\": [\"31263281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARAF-mediated resistance to the RAF dimer inhibitor belvarafenib requires both kinase activity and dimerization: ARAF kinase-domain mutations found in resistant melanoma cells and patient ctDNA form active dimers in the presence of belvarafenib; dimer-containing mutant ARAF is active under inhibitor conditions.\",\n      \"method\": \"Belvarafenib-resistant cell line generation; ctDNA sequencing from patients; ARAF mutant dimerization assays; kinase activity assays; panel of type II RAF inhibitors\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic characterization confirmed in both cell lines and patient samples with kinase and dimerization assays, replicated across multiple RAF inhibitors\",\n      \"pmids\": [\"33953400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LXH254 (type II RAF inhibitor) preferentially inhibits BRAF and CRAF but largely spares ARAF; ARAF-mediated resistance to LXH254 requires both kinase function and dimerization; in RAS-mutant cells expressing only ARAF, LXH254 paradoxically activates MAPK signaling; loss of ARAF sensitizes RAS-mutant cells to LXH254.\",\n      \"method\": \"Biochemical kinase profiling; ARAF/BRAF/CRAF ablation (isogenic cell lines); kinase-impaired and dimer-deficient ARAF variants; paradoxical activation assays; xenograft models\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic RAF paralog ablation panel with kinase-dead and dimer-deficient mutants plus in vivo xenograft, multiple orthogonal methods\",\n      \"pmids\": [\"33355204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARAF activates RAS in a kinase-independent manner by binding to RAS and displacing the GTPase-activating protein NF1, thereby antagonizing NF1-mediated RAS-GTP hydrolysis, reducing ERK-dependent negative feedback on RAS, and increasing RAS-GTP levels; ARAF amplification in EGFR-mutant lung cancers confers resistance to EGFR inhibitors via this mechanism.\",\n      \"method\": \"Co-immunoprecipitation of ARAF-RAS-NF1 complexes; RAS-GTP pull-down; kinase-dead ARAF expression; ARAF overexpression/depletion; EGFR inhibitor resistance assays; combination with SHP2 inhibitor\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic dissection with kinase-dead mutant, direct protein interaction assays, and functional rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"35613620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRAF:ARAF heterodimers are increased in KRAS-mutant cells (quantitative proteomics); depletion of both CRAF and ARAF rescues CRAF-loss phenotype; kinase-dead but not dimer-defective CRAF rescues growth, indicating that CRAF dimerization (including with ARAF) rather than kinase activity is required for maintaining appropriate MAPK signal intensity in KRAS-mutant tumors.\",\n      \"method\": \"Quantitative proteomics; siRNA depletion; rescue with kinase-dead and dimer-defective mutants; MAPK signaling assays; low-dose MEK/ERK inhibitor rescue\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative proteomics plus genetic rescue with structure-function mutants, single lab\",\n      \"pmids\": [\"35139374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARAF suppresses ERBB3 expression in a kinase-independent manner by inhibiting ERBB3 promoter activity through the transcription factor KLF5; ARAF depletion increases ERBB3-AKT signaling and promotes metastasis; reconstitution of ARAF in ARAF-depleted cells reverses enhanced ERBB3-AKT signaling.\",\n      \"method\": \"ARAF siRNA depletion; ERBB3 promoter reporter assay; AKT signaling assays; KLF5 identification; rescue experiments\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter assay plus kinase-independent rescue with transcription factor pathway placement, single lab\",\n      \"pmids\": [\"35302851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Trihydrophobin 1 (TH1) specifically binds to A-Raf kinase (but not B-Raf or C-Raf) both in vitro and in vivo; TH1 inhibits A-Raf kinase activity but does not affect B-Raf or C-Raf kinase activity; the A-Raf binding region of TH1 maps to amino acids 1–372; A-Raf kinase activity promotes binding to TH1.\",\n      \"method\": \"Co-immunoprecipitation; in vitro binding; Raf kinase assay; confocal colocalization; stable transfection with cell cycle analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro binding plus kinase assay with domain mapping, single lab\",\n      \"pmids\": [\"14684750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A-Raf associates with activated EGF receptor complexes and with PDGF receptor (PDGFR) complexes independently of prior PDGF treatment; expression of partially activated A-Raf mutant decreases tyrosine phosphorylation of PDGFR on Y857 and Y1021 (but not other docking sites) and alters PLCγ1 and PI3K activation.\",\n      \"method\": \"Co-immunoprecipitation; phospho-specific Western blotting of PDGFR tyrosines; A-Raf mutant overexpression; PLCγ1 and PI3K activity assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-IP with downstream signaling readouts, limited mechanistic depth in abstract, single lab\",\n      \"pmids\": [\"15763428\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARAF is a serine/threonine kinase with intrinsically lower MEK kinase activity than BRAF or CRAF, regulated by isoform-specific phosphorylations (including an IH-segment and key N-region residues), that participates in the RAS–RAF–MEK–ERK cascade through multiple mechanisms: it can selectively activate MEK1 (but not MEK2) downstream of growth factor receptors, dimerizes (homo- and hetero-) to activate MEK1/ERK in a dimerization-dependent manner, scaffolds BRAF:CRAF heterodimers, directly phosphorylates Smad2 in a MEK-independent manner to attenuate TGF-β/Nodal signaling, sequesters and inactivates pro-apoptotic MST2 kinase (independent of its kinase activity), and activates RAS in a kinase-independent manner by displacing the GTPase-activating protein NF1; its subcellular localization (mitochondria vs. plasma membrane, regulated by KSR2) controls its anti-apoptotic vs. pro-apoptotic state, alternative splicing produces a dominant-negative short isoform that suppresses RAS-ERK signaling, and kinase-domain mutations can confer oncogenic gain-of-function or resistance to RAF dimer inhibitors.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ARAF is a serine/threonine kinase of the RAF family that functions in the RAS–RAF–MEK–ERK cascade but possesses intrinsically lower MEK kinase activity than BRAF or CRAF, phosphorylating MEK1 hundreds-fold less efficiently in vitro [#0]. This low basal activity is set by isoform-specific N-region constraints, where residues such as Y296 and G300 restrain catalytic output and engineered substitutions can render the kinase constitutively active [#13], with additional positive regulation supplied by an isoform-specific hinge segment and a MEK-binding serine (S432) identified by phosphosite mapping [#14]. ARAF selectively activates MEK1 but not MEK2 downstream of growth factor receptors [#2], and its activation is dimerization-dependent: it homo- and heterodimerizes, and dimer-deficient mutants fail to bind MEK1 or activate ERK [#19]. Genetic loss-of-function studies show ARAF is largely dispensable alone—knockout MEFs retain normal ERK signaling with compensatory BRAF/CRAF upregulation [#8]—but ARAF and RAF-1 act redundantly to drive transient MEK/ERK phosphorylation and G1/S progression [#10], and ARAF scaffolds and stabilizes BRAF:CRAF heterodimers [#17]. Beyond canonical kinase signaling, ARAF carries out several kinase-independent functions: it sequesters and inactivates the pro-apoptotic kinase MST2 to block apoptosis, a function gated by mitochondrial versus plasma-membrane localization controlled by KSR2 [#9, #24]; it activates RAS by binding RAS and displacing the GAP NF1 to raise RAS-GTP [#30]; and it suppresses ERBB3 transcription via KLF5 [#32]. ARAF also directly phosphorylates Smad2 in its linker region (S253) in a MEK/ERK-independent manner to attenuate Nodal/Smad2 signaling during development [#18]. Alternative splicing produces a truncated dominant-negative isoform that retains the RAS-binding domain and suppresses RAS-ERK signaling, regulated by hnRNP H, hnRNP A2 and c-Myc [#16, #22]. Recurrent gain-of-function kinase-domain mutations (e.g. S214P/S214C, N217I) drive oncogenic MAPK activation and a lymphatic/lymphangiogenic phenotype rescued by MEK inhibition [#21, #27], and ARAF kinase-domain mutations confer resistance to type II RAF dimer inhibitors in a manner requiring both kinase activity and dimerization [#28, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that ARAF is a functional RAF kinase but quantitatively the weakest activator of MEK, defining the central puzzle of its distinct regulation.\",\n      \"evidence\": \"Inducible Raf:ER fusion system with direct in vitro kinase comparison across all three RAF isoforms\",\n      \"pmids\": [\"7565795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not explain the structural basis of low activity\", \"Did not identify ARAF-specific substrates beyond MEK\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined ARAF as a MEK1-selective kinase coupled to specific receptor and second-messenger inputs distinct from c-Raf, showing isoform specialization at the substrate and regulatory level.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro kinase assays, and pharmacological perturbation in HeLa and cardiomyocytes\",\n      \"pmids\": [\"8621729\", \"7592840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MEK1 vs MEK2 selectivity mechanism not structurally resolved\", \"Single-lab biochemical readouts\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified the kinase-domain regulatory residues and CK2β as activity modulators, beginning to explain how ARAF catalytic output is constrained and tuned.\",\n      \"evidence\": \"Site-directed mutagenesis with transformation/kinase readouts; yeast two-hybrid and Sf9 co-expression kinase assays\",\n      \"pmids\": [\"9285556\", \"9042966\", \"9042965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of CK2β regulation not established\", \"Physiological phosphorylation state of the regulatory residues unmapped\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Placed ARAF as the primary Raf coupling PI3-K to MEK-ERK in hematopoietic cells, distinguishing its upstream wiring from BRAF/CRAF.\",\n      \"evidence\": \"PI3-K inhibitors, dominant-negative isoforms, and IP kinase assays in IL-3-dependent cells\",\n      \"pmids\": [\"10066754\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of PI3-K-to-ARAF coupling not defined here\", \"Cell-type generality unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed ARAF subcellular targeting (mitochondria) and a phosphotyrosine-independent association with PI3-kinase p85, hinting at non-canonical localization and binding modes.\",\n      \"evidence\": \"Mitochondrial fractionation with immunogold EM; phage display, co-IP and in vitro binding for p85\",\n      \"pmids\": [\"10848612\", \"10967104\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of mitochondrial localization unresolved at this stage\", \"hTOM/hTIM interactions not functionally validated\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed ARAF is dispensable for ERK signaling alone due to BRAF/CRAF compensation, reframing its role as specialized or redundant rather than essential to the core cascade.\",\n      \"evidence\": \"Gene-targeted ARAF knockout MEFs and ES cells with functional readouts\",\n      \"pmids\": [\"11821947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test combined RAF loss\", \"Tissue-specific or non-ERK roles not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified the first kinase-independent anti-apoptotic role of ARAF via MST2 sequestration and an ARAF-specific inhibitor TH1, opening non-canonical signaling functions.\",\n      \"evidence\": \"siRNA knockdown with MST2 epistasis and apoptosis assays; co-IP and kinase assays for TH1 binding\",\n      \"pmids\": [\"20145135\", \"14684750\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of MST2 sequestration unresolved\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated functional redundancy of ARAF with RAF-1 in driving transient ERK signaling and cell cycle entry, resolving the discrepancy with the single-knockout phenotype.\",\n      \"evidence\": \"ARAF/RAF-1 double-knockout MEFs with cell cycle and phospho-MEK/ERK analysis; lipid binding assays\",\n      \"pmids\": [\"15856007\", \"15736953\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of selectivity for transient vs sustained ERK unclear\", \"Physiological role of phosphoinositide binding not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapped the N-region residues that impose ARAF's low basal activity, providing a structural rationale for its weak kinase output relative to other RAFs.\",\n      \"evidence\": \"Site-directed mutagenesis with kinase assays and modeling from BRAF structure; co-IP metabolic studies for M2-PK\",\n      \"pmids\": [\"17613527\", \"18225557\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No crystal structure of ARAF kinase domain\", \"M2-PK interaction is low-confidence and mechanistically thin\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined in vivo ARAF phosphosites controlling MEK binding (S432) and activation (IH-segment), refining the activation logic of the kinase.\",\n      \"evidence\": \"Mass spectrometry plus mutagenesis with in vitro kinase assays and EGF stimulation\",\n      \"pmids\": [\"18662992\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinases responsible for these phosphorylations not identified\", \"Single-lab phosphosite mapping\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established that c-Myc/hnRNP H-controlled splicing produces a dominant-negative ARAF(short) that suppresses RAS-ERK, linking isoform choice to pathway output.\",\n      \"evidence\": \"c-Myc and hnRNP H manipulation, splice-isoform RT-PCR, and RAS-GTP/ERK assays\",\n      \"pmids\": [\"21512137\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological triggers of splicing switch in vivo unclear\", \"Quantitative isoform ratios in tissues not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed ARAF is not redundant with CRAF and scaffolds BRAF:CRAF heterodimers under RAF inhibitor conditions, defining a structural role distinct from catalysis.\",\n      \"evidence\": \"Co-IP, knockdown/overexpression, RAF inhibitor treatment, and transformation assays\",\n      \"pmids\": [\"22926515\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dimer interface stoichiometry not fully resolved\", \"Endogenous relevance vs overexpression unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified Smad2 as a direct MEK-independent ARAF substrate, establishing a developmental signaling role outside the canonical MAPK cascade.\",\n      \"evidence\": \"In vitro kinase assay with S253 mutagenesis and zebrafish knockdown with rescue\",\n      \"pmids\": [\"23591895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Regulation of ARAF-Smad2 activity in mammalian development not mapped\", \"Crosstalk with MEK-ERK substrate selection unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that ARAF activation strictly requires dimerization, unifying its inhibitor-induced and growth-factor-driven activation with a shared mechanistic requirement.\",\n      \"evidence\": \"Recombinant protein competition, dimer-deficient mutants, siRNA, and 3D spheroid invasion assays\",\n      \"pmids\": [\"25097033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of obligate dimer partners in vivo not fully defined\", \"Dimer-specific conformational change not structurally captured\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified recurrent oncogenic ARAF kinase-domain mutations in LCH, lung, and other cancers that produce hyperactive, drug-targetable MAPK kinases.\",\n      \"evidence\": \"In vitro kinase and transformation assays with vemurafenib/sorafenib sensitivity; whole-genome sequencing\",\n      \"pmids\": [\"24652991\", \"24569458\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mutation-specific mechanism of activation not fully resolved\", \"Clinical response durability not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed hnRNP A2-driven splicing reduces dominant-negative ARAF and activates RAS-MAPK in hepatocellular carcinoma, reinforcing splicing as an oncogenic switch.\",\n      \"evidence\": \"hnRNP A2 siRNA, splice-isoform RT-PCR, EGF-induced ERK assays, and tumor formation\",\n      \"pmids\": [\"24572810\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality across tumor types not tested\", \"Direct hnRNP A2 binding sites on Araf pre-mRNA not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Confirmed additional oncogenic ARAF mutations (N217I, G322S) drive MAPK activation in cholangiocarcinoma, extending the mutational spectrum.\",\n      \"evidence\": \"RNA/exome sequencing with MAPK activation and transformation assays\",\n      \"pmids\": [\"25608663\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Differential potency of mutations not benchmarked\", \"Therapeutic implications not tested in vivo\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed localization (mitochondria vs plasma membrane, set by KSR2) determines whether ARAF blocks or permits MST2-mediated apoptosis, linking spatial control to cell fate.\",\n      \"evidence\": \"Confocal imaging, fractionation, KSR2 knockdown, and apoptosis assays in a differentiation model\",\n      \"pmids\": [\"26891695\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of KSR2-controlled relocalization not defined\", \"In vivo relevance during tissue differentiation untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined the recurrent S214P gain-of-function mutation as a cause of lymphatic anomalies driven by ERK hyperactivation and reversible by MEK inhibition, establishing a disease-relevant mechanism.\",\n      \"evidence\": \"Lentiviral expression, ERK/lymphangiogenesis/junction assays, zebrafish model, and trametinib rescue\",\n      \"pmids\": [\"31263281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why S214 loss is specifically activating not structurally resolved\", \"Endothelial-specific cofactors not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established ARAF as a clinically important driver of resistance to type II RAF dimer inhibitors, requiring both kinase activity and dimerization, and showing ARAF can paradoxically maintain MAPK signaling under inhibition.\",\n      \"evidence\": \"Resistant cell lines, patient ctDNA sequencing, dimerization/kinase mutants, and xenografts across multiple RAF inhibitors\",\n      \"pmids\": [\"33953400\", \"33355204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Strategies to co-target ARAF dimers not validated clinically\", \"Why ARAF is spared by these inhibitors structurally not fully defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Uncovered kinase-independent ARAF functions—RAS activation via NF1 displacement and ERBB3 suppression via KLF5—that broaden its role beyond a MEK kinase and explain inhibitor and EGFR-therapy resistance.\",\n      \"evidence\": \"Co-IP of ARAF-RAS-NF1 complexes, RAS-GTP pull-downs, kinase-dead mutants, promoter reporters, and rescue experiments\",\n      \"pmids\": [\"35613620\", \"35302851\", \"35139374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of NF1 displacement not solved\", \"Balance between ARAF's kinase and scaffold functions in tumors unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ARAF's multiple kinase-dependent and kinase-independent activities are integrated and spatially partitioned within a single cell, and whether its non-canonical functions are therapeutically separable, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of full-length ARAF or its dimers\", \"Unknown how localization, splicing, and partner choice are co-regulated\", \"Relative contribution of kinase vs scaffold roles in disease undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 18]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 4, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 30, 31]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [6, 24]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [11, 24]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 19, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [27, 28, 30]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 24]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"complexes\": [\"BRAF:CRAF heterodimer\", \"ARAF-RAS-NF1 complex\"],\n    \"partners\": [\"MEK1\", \"BRAF\", \"CRAF\", \"MST2\", \"NF1\", \"RAS\", \"SMAD2\", \"KSR2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}